Concepta plc (AIM: CPT), the pioneering UK healthcare company and developer of a proprietary platform and suite of products targeted at the personalised mobile health market with a primary focus on women’s fertility and specifically unexplained infertility, is pleased to announce that the Company has received formal confirmation of a £600,000 sales order (the “Order”) (RMB 5,058,196).
The order for 5,200 of Concepta’s myLotus meters was previously announced on 6 November 2017 and has been placed by ShanDong WeiHai HaiChen Pharmaceutical Co. Ltd in China. Revenues from this order will be realised in Q4 2017.
The order has been received from ShanDong WeiHai HaiChen Pharmaceutical Co. Ltd based in WeiHai City, ShanDong Province and covers the territories Beijing, Shanghai, ShanDong Province and Henan Province.
Erik Henau, CEO of Concepta plc said:
“I am very pleased to be able to confirm the receipt of this significant order for our myLotus product. We are now starting to see our considerable investment in relationship building, marketing, and setting up manufacturing, logistics and distribution begin to bear fruit in China. We expect to be able to announce further orders in the coming months and I look forward to updating shareholders in due course.”
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned